Change over period: —
NSE · SYNGENE
SYNGENE
-34.5% from the 52-week high · +25.7% above the low
Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 6,847 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. The company serves the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
The short version. SYNGENE reported revenue of ₹833 crore for Sep 2026, down 8.6% from a year earlier. Net profit was ₹32 crore (down 52.2% year on year). Return on equity was 6.5% in Mar 2026. Promoter holding was 52.59% in Sep 2026, down 0.14 points over 8 quarters.
1 · The price
How has the stock traded?
SYNGENE trades 34.5% below its 52-week high and 25.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹833 cr.
Sep 2026 net profit of ₹32 cr.
3.5 pts lower than a year earlier.
Revenue compounded at 5.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 833 | 736 | 1036 | 917 | 911 | 874 | 1018 | 944 |
| Net profit | 32 | -9 | 148 | 15 | 67 | 87 | 183 | 131 |
| Net margin % | 3.9 | -1.2 | 14.3 | 1.6 | 7.4 | 9.9 | 18.0 | 13.9 |
| EPS (₹) | 0.8 | -0.22 | 3.67 | 0.37 | 1.67 | 2.15 | 4.55 | 3.26 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3739 | 3642 | 3489 | 3193 | 2604 | 2184 | 2012 | 1826 |
| Net profit | 317 | 496 | 510 | 464 | 396 | 405 | 412 | 332 |
| Net margin % | 8.5 | 13.6 | 14.6 | 14.5 | 15.2 | 18.5 | 20.5 | 18.2 |
| EPS (₹) | 7.86 | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 | 10.3 | 8.29 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.5% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 6.5 | 10.5 | 12.0 | 12.8 |
| Return on capital % | 8.3 | 13.2 | 13.3 | 13.8 |
| EBITDA margin % | 24.0 | 30.8 | 30.6 | 30.8 |
| Net margin % | 8.3 | 13.4 | 14.2 | 14.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 5.3% | 11.1% |
| Profit CAGR | -12.0% | -4.8% |
4 · The owners
Who holds it, and are they adding?
Down 0.14 pts over 8 quarters.
Down 10.5 pts over 8 quarters.
Up 9.77 pts over 8 quarters.
+16 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 52.73 | 52.73 | 52.68 | 52.68 | 52.68 | 52.68 | 52.59 | 52.59 | -0.14 |
| FII | 20.64 | 19.47 | 16.5 | 16.31 | 14.96 | 13.9 | 11.82 | 10.14 | -10.5 |
| DII | 19.53 | 21.5 | 24.05 | 24.62 | 25.84 | 26.44 | 28.02 | 29.3 | +9.77 |
| Public | 6.8 | 6.0 | 6.45 | 6.08 | 6.22 | 6.69 | 7.14 | 7.56 | +0.76 |
Mutual fund holdings · Oct 2026
125 schemes hold this stock
109 the month before.
- ICICI Prudential Healthcare Fund3.76% of NAV
- TATA INDIA PHARMA & HEALTHCARE FUND3.17% of NAV
- Nippon India Focused Fund3.03% of NAV
- Bandhan Healthcare Fund2.73% of NAV
- THE WEALTH COMPANY MULTI CAP FUND2.58% of NAV
- The Wealth Company Mid cap fund2.33% of NAV
- Mirae Asset Focused Fund2.07% of NAV
- DSP Focused Fund1.91% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SYNGENE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about SYNGENE
What is the SYNGENE share price?
SYNGENE (SYNGENE) last closed at ₹438.50, up 0.85% on the day. Its 52-week range is ₹346.00 to ₹663.85.
What is the market cap of SYNGENE?
SYNGENE has a market capitalisation of about ₹17,319 crore. Its price-to-earnings ratio is 94.6.
How are SYNGENE's latest results?
SYNGENE reported revenue of ₹833 crore for Sep 2026, down 8.6% from a year earlier. Net profit was ₹32 crore (down 52.2% year on year). Return on equity was 6.5% in Mar 2026. Promoter holding was 52.59% in Sep 2026, down 0.14 points over 8 quarters.
Who owns SYNGENE?
As of Sep 2026, shareholding was: Promoter 52.59%, FII 10.14%, DII 29.3%, Public 7.56%.
How many mutual funds hold SYNGENE?
125 mutual fund schemes held SYNGENE in October 2026. That compares with 109 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jun 2026 · Final Dividend - Rs. 1.25
- 27 Jun 2025 · Final Dividend - Rs. 1.25
- 28 Jun 2024 · Final Dividend - Rs. 1.25
- 30 Jun 2023 · Final Dividend - Rs. 0.5
- 30 Jun 2023 · Special Dividend - Rs. 0.75
- 30 Jun 2022 · Special Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.